TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has arranged a shares for debt transaction to settle an aggregate of $424,767.07 in interest accrued up to December 31, 2021 on all five of the deferred convertible notes outstanding … Read more
TORONTO, Feb. 03, 2022 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that a scientific team led by Dr. Daniel Muruve at the University of Calgary, and their collaborators, have published a paper in the journal Science Advances describing the mechanism of action for dipeptidase-1 … Read more
LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys common in several indications, including moderate to severe cases of COVID-19, regardless of variant type. TORONTO, Jan. 04, 2022 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch Biopartners”, “Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: … Read more
LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys which is common in moderate to severe cases of COVID-19, regardless of variant type. LSALT is the first novel therapeutic to join the Canadian Treatments for COVID-19 trial, a multi-centre adaptive, randomized, open-label, controlled clinical trial … Read more
TORONTO, Oct. 15, 2021 (GLOBE NEWSWIRE) — At the request of the Investment Industry Regulatory Organization of Canada (IIROC), Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) wishes to confirm that the Company’s management is unaware of any undisclosed material change in the Company’s operations that would account for the … Read more
August 05, 2021 06:30 ET | Source: Arch Biopartners TORONTO, Aug. 05, 2021 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today provided an update that the analysis of the results of … Read more
July 14, 2021 07:00 ET | Source: Arch Biopartners TORONTO, July 14, 2021 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today that Arch scientists have been awarded a Canadian Institutes … Read more
June 10, 2021 07:20 ET | Source: Arch Biopartners TORONTO, June 10, 2021 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today it has filed a new provisional patent application with … Read more
May 04, 2021 07:00 ET | Source: Arch Biopartners TORONTO, May 04, 2021 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced it has completed enrollment for its Phase II study … Read more
Arch Biopartners is a clinical stage company developing new drug candidates for treating organ damage caused by inflammation Novel Mechanism of Action – selective dipeptidase-1 (DPEP-1) antagonists that prevent leukocyte adhesion to endothelial cells reducing inflammation and subsequent organ damage Cilastatin and Arch drug Metablok are the only known DPEP-1 antagonists that have successfully completed … Read more